All Posts

by John F. Heerdink, Jr. September 9, 2025

The InterGroup Corporation’s Hilton SF Stake Puts It at the Heart of San Francisco’s AI-Driven Revival – ( $AAPL $INTG $NVDA )

The InterGroup Corporation (NASDAQ: INTG) is emerging as a compelling turnaround story in 2025, combining solid real estate assets with a strategic push to unlock shareholder value and capitalize on market dislocations.

Recent Highlights and Stock Momentum

In August, InterGroup’s (INTG) shares surged by 58% after a prolonged period of declines and is continuing to edge higher so far in September closing at $19.01 on Tuesday, September 9, possibly signaling renewed investor confidence. With interest rates poised to decline, InterGroup may further positioned as a compelling investment opportunity to look further into this year.

Underlying Business Strengths

The company has a diverse portfolio of real estate including 16 multifamily apartment complexes across the U.S., a commercial real estate property and a 75% stake in the iconic Hilton San Francisco Financial District Hotel. Located adjacent to Jackson Square where Joni Ives, the former Apple (AAPL) design executive, who has been acquiring properties in Jackson Square creating a surge in real estate prices in the Jackson Square area as he is building his new design firm LoveFrom and which has recently received a $6.5 billion offer from Open AI to become part of the Open AI organization. The hotel is also adjoining the iconic TransAmerica Pyramid building in the Financial District. It appears the hotel is located strategically considering all that is going on in San Francisco. Recently, NVIDIA’a (NVDA) Jensen Huang stated that San Francisco is thriving because of AI and was highlighted to be seeking office space in The City.

Financial Outlook and Valuation

Management’s capital discipline and strategic refinancings, including a headline-grabbing move at the Hilton San Francisco property earlier this year as The City rebounds on the broad shoulders of Artificial Intelligence related funding & investing, are seemingly priming InterGroup for margin expansion and improved cash flow. The company trades at a remarkably low ~.5x price-to-sales ratio—well below industry norms—and significantly below its intrinsic value.

Strategic Position and Growth Catalysts

With a footprint concentrated in high-demand markets like Texas, Southern California, & San Francisco, InterGroup seems to likely poised to benefit from demographic trends, rebounding hospitality revenues, and further capital recycling opportunities. The company’s mix of multifamily, commercial, and hospitality investments seems to position it as a diversified value play in the real estate sector.

Bottom Line

With disciplined management, a diverse portfolio, recent operational wins, and strong momentum and potentially lower interest rates. Most importantly seeing recently that management and corporate insiders were purchasing INTG stock gives us additional confidence that management is eating its own cooking and seemingly confidence in the companies future prospects. The InterGroup Corporation (INTG) is an interesting small-cap opportunity to consider for those looking for real estate exposure heading into year-end 2025 and beyond.

Sources

by John F. Heerdink, Jr. September 9, 2025

Anglo American and Teck Forge $53 Billion Copper Giant as Hecla Mining Surges ( $HL TECK-B.TO AAL.L $SLV )

London-listed Anglo American (AAL.L) and Canada’s Teck Resources (TECK-B.TO) have sealed a transformative, “merger of equals” deal that will reshape the mining landscape—creating a copper powerhouse with a combined market capitalization north of $53 billion, headquarters in Vancouver, and core operations spanning London and Johannesburg. As investors absorb this landmark news, Hecla Mining (HL) has emerged as a standout performer—riding strong Q2 results and surging silver prices to fresh 52-week highs and YTD returns over 105%, far outpacing the broader market.

Anglo American–Teck Merger

The deal, announced September 9, brings together Anglo American’s 44% Collahuasi stake with Teck’s nearby assets, positioning the new entity among the world’s top five copper producers, boasting annual output around 1.2 million metric tons. Anglo shareholders will own roughly 62%, Teck holders 38%, and a $4.5 billion dividend sweetens the arrangement for Anglo investors. This transaction is not only the biggest mining M&A of the decade, but also signals a strategic bet on copper—critical for both electric vehicles and AI datacenter infrastructure—amid rising global demand.

Industry Minister Melanie Joly highlighted the Canadian commitment, with Vancouver set as global HQ and a pledge to maintain senior management in-country. Market participants welcomed the deal: Anglo shares jumped 10% and Teck surged over 14% in early trading, reflecting optimism about the new copper champion’s prospects.

Hecla Mining: Resilient Performance

Against this backdrop, Hecla Mining delivered a record quarter, reporting nearly $930 million in Q2 revenue—buoyed by robust silver and gold output, EBITDA margins of 34%, and net income tracking at $57 million. These better-than-anticipated results powered HL shares to intra-week gains of 12–13% and a 52-week high of $10.18, marking a remarkable 62% increase over the past year and 105% YTD, compared to the S&P 500’s more modest 10% YTD climb.

Hecla’s strong fundamentals—low debt, healthy liquidity, and strategic investment in flagship mines like Greens Creek and Keno Hill—seem to be driving market confidence. The company projects silver output between 35.5–39 million ounces for 2025, and analysts are reportedly upgrading expectations for net income and continued earnings momentum.

Strategic Landscape

The Anglo–Teck deal underscores the sector’s appetite for copper and strategic scale, while Hecla’s performance confirms that precious metals miners are also enjoying tailwinds from global uncertainty and commodity rallies. For investors seeking exposure to resource leadership, both Anglo Teck’s consolidation play and Hecla Mining’s operational excellence present compelling narratives for the year ahead.

Sources

by John F. Heerdink, Jr. September 6, 2025

How $1,000 in NVIDIA’s 1999 IPO Became $6.7 Million: The Vision of Jensen Huang – ( $NVDA $SPY $QQQ )

NVIDIA’s (NVDA) meteoric rise from Silicon Valley upstart to AI infrastructure leader is deeply intertwined with the vision and resilience of its founder-CEO, Jensen Huang. An immigrant who experienced hardship and displacement as a youth in Taiwan and the U.S., Huang sharpened both his technical and business acumen before founding NVIDIA in 1993. He has remained at the helm ever since, guiding the company through crises, innovation booms, and transformative pivots.

Jensen Huang: Founder, Strategist, Risk-Taker

Huang’s background—engineering degrees from Oregon State and Stanford, stints at LSI Logic and AMD, and a childhood that demanded adaptability—prepared him for NVIDIA’s tumultuous beginnings. The company faced near-bankruptcy in the late 1990s and early 2000s, but Huang’s willingness to make bold bets, like pivoting product architectures and laying off staff to survive, underscored his blend of caution and risk-taking. Stories of “thirty days from going out of business” became part of NVIDIA’s lore, reflecting the urgency and hunger he instilled in the culture.

Leadership Through Tech Revolutions

For over three decades, Huang has shaped NVIDIA into a cornerstone of modern computing. He steered the company from gaming graphics to the center of the digital economy—unlocking value not just in entertainment, but in deep learning, high-performance computing, and AI infrastructure. Huang’s technical vision was complemented by relentless communication: his iconic leather jackets, direct public speaking, and ability to explain complex technology for broad audiences became NVIDIA trademarks.

Rewards for Investors and the Industry

Under Huang’s stewardship, NVIDIA’s market value has multiplied, surpassing $4 trillion in 2025 and transforming fortunes for early investors. A $1,000 investment on January 22, 1999 would be worth approximately $6,680,800 as of September 5, 2025—an astronomical gain fueled by multiple stock splits and escalating product relevance. Huang’s own net worth has soared over $150 billion, earning him repeated accolades as one of the world’s most influential business leaders.

Enduring Legacy and Impact

Through product setbacks, competitive threats, and shifting tech landscapes, Jensen Huang consistently emphasized perseverance, curiosity, and team trust. He remains a tenacious force in Silicon Valley, with a leadership style mixing humility, technical immersion, and a builder’s mindset—now revered by CEOs and engineers alike.

The Sum…

The story of NVIDIA is inseparable from Huang’s journey: from a Denny’s napkin business plan to redefining global computation, his fingerprints are on every epoch-defining chapter the company has written. With AI poised to reshape entire industries, Huang and NVIDIA seem set not just to participate in that future—but to invent it.

Sources:

by John F. Heerdink, Jr. September 3, 2025

Serina Therapeutics (SER): How Steven Ledger’s Vision is Seeking to Transform Parkinson’s Treatment With Weekly Injections

Serina Therapeutics (NYSE American: SER) is standing out in the biotech world for its push to simplify Parkinson’s care, moving from several daily pills to a once-weekly injection—a mission led by CEO Steven Ledger, who appears front and center in the company’s recent video announcement. In the video, Ledger articulates Serina’s core philosophy: “Our technology is designed to get into that [therapeutic] window quickly and to stay in that window for a week and with a single subcutaneous injection.”

Steven Ledger’s Vision

Steven Ledger, who took the helm as CEO in March 2024 after notable experience in finance and biotech leadership, is focused on practical problem-solving for longstanding drug delivery challenges in neurodegenerative diseases. Ledger emphasizes the shortcomings of oral levodopa—while it may initially work well with a twice-daily routine, by year five patients are often forced to take it up to eight times daily, with inevitable “drop-outs” from the effective range, especially overnight.

Breaking Through in Parkinson’s

Serina’s once-weekly subcutaneous injection seeks to “replace the burden of multiple daily doses” by maintaining steady therapeutic levels—what Ledger refers to as keeping therapies in the crucial “sweet spot” for maximum efficacy. This approach is powered by the company’s POZ platform, promising a new level of symptom control and quality of life for those affected by advanced Parkinson’s disease.

Regulatory and Market Traction

The company’s momentum is palpable following recent FDA support for its clinical plan and a ~50% stock surge, signaling investor confidence in both the platform technology and Ledger’s leadership. As clinical trials ramp up and Ledger continues to champion innovations targeting the “therapeutic window,” Serina Therapeutics is fast becoming a biotech name to watch—especially for patients, physicians, and Wall Street alike.

Sources

by John F. Heerdink, Jr. September 2, 2025

Global Central Banks Drive Gold to New Record, Surpassing U.S. Bonds in Portfolios – ( $GLD $SPY )

Gold has achieved a historic milestone in 2025, with central banks now holding more gold in their reserves than U.S. Treasuries for the first time since 1996—a shift signaling profound changes in global finance and monetary management.

Central Banks Shift to Gold

Driven by escalating geopolitical risks, persistent global trade uncertainties, and concerns over the stability of the U.S. dollar, central banks have increasingly favored gold as their primary reserve asset. As of May 2025, official central bank gold holdings reached approximately 36,344 tonnes, surpassing both the value and strategic importance of U.S. Treasuries in their portfolios. During the early 2020s, annual gold purchases by central banks averaged just 400–500 tonnes, but this number has more than doubled in recent years—for example, 1,082 tonnes in 2022, 1,037 tonnes in 2023, and a record 1,180 tonnes in 2024.

Reasons for Accelerated Gold Buying

This trend is rooted in several factors:

Diversification: Central banks aim to reduce overreliance on the U.S. dollar and diversify foreign exchange reserves, with 76% of surveyed central banks projecting a higher share of gold in their reserves over the next five years.
Geopolitical and Trade Uncertainty: Recent years have seen a rise in sanctions risks and trade frictions, particularly affecting nations such as Russia and China, who are aggressively increasing their gold reserves to bolster economic leverage and crisis resilience.
Hedge Against Currency and Market Instability: Gold’s long-standing role as a hedge against inflation, economic volatility, and currency debasement remains central to reserve managers’ decisions.

Impact on Global Markets

Gold’s ascent to record highs—topping $3,500 per ounce in 2025, hitting $3,595.20/oz Tuesday—reflects both robust central bank demand and broader investor appetite for safe-haven assets. The World Gold Council’s surveys indicate that 43% of central bankers plan to expand gold holdings in the next year, and 95% expect further global increases in official gold reserves. At the same time, foreign holdings of U.S. Treasuries have stagnated or declined, reflecting both waning international appetite for U.S. debt and confidence in gold’s enduring value.

Leading Holders and Strategic Shifts

The United States remains the single largest gold holder globally, with over 8,100 tonnes, followed by countries like Germany, Italy, France, Russia, and China. However, rapid accumulation by emerging-market central banks underscores a broad, structural transformation in reserve strategies—sometimes called a “global rebalancing”—that could have lasting implications for international finance.

The Road Ahead

Overall, as the global economic landscape grows ever more uncertain, and faith in the dollar-centric system wanes, gold’s prominence as a reserve asset and a symbol of financial power is once again on the rise.

Sources

by John F. Heerdink, Jr. September 2, 2025

Beyond Daily Pills: Eupraxia’s Annual Therapy Could Revolutionize Eosinophilic Esophagitis Management – ( $EPRX $IBB $XBI )

Eupraxia Pharmaceuticals (NASDAQ: EPRX) is defining a new frontier in the treatment of eosinophilic esophagitis (EoE) with its innovative candidate, EP-104GI. This investigational therapy, developed with Eupraxia’s proprietary DiffuSphere™ technology, delivers long-lasting and locally targeted steroid treatment directly into the esophageal wall—offering hope for a patient population long underserved by current therapies.

Groundbreaking Clinical Progress

In its ongoing RESOLVE Phase 1b/2a trial, Eupraxia has achieved results that stand out in the field. The latest one-year results show that 67% of patients in Cohort 5 (48mg dose, 4mg per site) remained in clinical remission twelve months after a single treatment with EP-104GI. All cohorts followed for at least nine months demonstrated durable, clinically meaningful improvements in esophageal tissue health as measured by the EoE Histological Scoring System (EoEHSS). Remarkably, no serious adverse events nor cases of oral or gastrointestinal candidiasis—a common drawback of steroid-based treatments—were reported throughout the clinical trial duration.

Dr. James A. Helliwell, CEO of Eupraxia, captured the significance, stating, “We believe the prolonged duration of symptom response that we are seeing with EP-104GI is truly a unique clinical result and will potentially provide a once-a-year therapy to patients with EoE. And overall, we continue to see that the more drug we deliver to the tissues, the better the results.” Eupraxia envisions a future where patients could receive EP-104GI during their routine annual endoscopy—transforming the care paradigm and addressing a harsh reality of EoE: the burden of daily medication or weekly injections.

The company recently launched a pivotal Phase 2b, global, randomized, placebo-controlled trial, enrolling at least 60 participants at up to 25 sites, seeking to reinforce confidence in its robust safety and efficacy profile.

Understanding Eosinophilic Esophagitis

EoE is a chronic, immune-mediated inflammatory disease of the esophagus, marked by pathological infiltration of eosinophils (a type of white blood cell) that causes pain, difficulty swallowing, and can lead to strictures or food impactions. Recent research indicates that at least 472,000 people in the United States are affected—a dramatic rise attributed to greater awareness, diagnosis, and possibly environmental factors. The condition often seriously impairs quality of life, affecting both children and adults.

Current Treatment Landscape and Its Shortcomings

Historically, EoE has been managed by three main strategies:

Swallowed topical corticosteroids, usually repurposed asthma drugs, are taken daily and must coat the esophagus, but require stringent adherence and have risks including oral/esophageal candidiasis and symptom relapse when stopped.
Proton-pump inhibitors (PPIs) offer partial efficacy and help some patients but rarely induce sustained remission.
Elimination diets—removing common trigger foods—can be effective but are notoriously challenging for most patients to maintain and can disrupt daily life.
Endoscopic dilation is reserved for severe stricture, providing only symptomatic relief and no effect on disease activity.

Despite these approaches, many patients still endure recalcitrant symptoms, repeated procedures, and the inconvenience of chronic therapy. A truly disease-modifying, long-duration treatment remains a significant unmet need in this rapidly growing disease population.

Eupraxia Pharmaceuticals’ Proprietary DiffuSphere™ Technology

Eupraxia Pharmaceuticals’ proprietary DiffuSphere™ technology is a novel, polymer-based microsphere drug delivery platform designed to optimize where, when, and how medications are released in the body. Unlike conventional delivery systems, which can result in fluctuating drug levels and unwanted side effects, DiffuSphere™ encapsulates a pure drug core in a microns-thick polymer shell. This outer membrane enables the drug’s controlled, predictable release at a constant, well-defined rate—directly into the targeted tissue while minimizing systemic exposure.

Key advantages of DiffuSphere™ include:

Precision Targeting: Releases drugs directly into specific tissues such as the esophagus or knee, resulting in extremely high local concentrations and reduced exposure elsewhere, which can limit side effects.
Extended Duration: Capable of maintaining therapeutic drug levels for over six months after a single administration, offering long-lasting efficacy in chronic conditions like EoE and osteoarthritis.
Reduced Polymer Burden: Uses much less polymer than traditional systems, potentially decreasing complications from polymer degradation.
Versatility: Successfully demonstrated for a broad array of drug types—steroids, anesthetics, and anti-infectives—across multiple body sites.

Clinical and preclinical studies have shown DiffuSphere™ technology can deliver drugs such as fluticasone propionate in EoE patients with more than 1,000 times greater tissue concentrations than oral delivery, yet with lower systemic levels and fewer side effects. The platform’s programmability and tolerability suggest broad application potential for improving the efficacy and safety of both novel and FDA-approved therapies.

Business Momentum, Analyst Confidence, and Industry Leadership

Eupraxia’s progress is further amplified by its sound balance sheet—nearly $20 million in cash as of mid-2025—and a strong presence at major industry and investor conferences this year, including Canaccord Growth, Citi Biopharma, Cantor Global Healthcare, and H.C. Wainwright events. Wall Street sentiment has turned notably bullish, reflected in consensus “Buy” ratings and heightened institutional investor interest. Out of six Wall Street analysts covering the stock in the past twelve months, all have issued “Buy” or “Strong Buy” ratings for Eupraxia. The consensus price target stands at $11—more than double its current trading level, reflecting analysts’ optimism about the company’s growth trajectory and clinical catalysts. In addition, large institutional players such as Scotia Capital, Royal Bank of Canada, and JPMorgan have notably increased holdings in recent quarters, underlining sector confidence in the long-term fundamentals.

The Road Ahead

With EP-104GI, Eupraxia Pharmaceuticals (NASDAQ: EPRX) is positioned at the forefront of a therapeutic revolution for EoE: its once-a-year, procedure-based approach could drastically simplify patients’ lives while delivering disease modification, not just symptom relief. As pivotal trial data readouts approach, clinicians and investors alike are watching for Eupraxia to set a new standard—and potentially, a new hope—for people living with EoE everywhere.

Sources

by John F. Heerdink, Jr. August 28, 2025

Eupraxia Pharmaceuticals (NASDAQ: EPRX) Accelerates Toward Key Clinical Milestones—Wall Street Remains Bullish

Eupraxia Pharmaceuticals (NASDAQ: EPRX) has recently achieved several pivotal milestones, signaling increased momentum in its late-stage clinical programs and drawing strong endorsements from Wall Street analysts, while shares of Eupraxia have risen ~100% over the last 12 months. The company’s clinical progress, financial positioning, and new data readouts have made it a focal point for both sector specialists and headline institutional investors, highlighting the unique promise of its proprietary Diffusphere™ technology platform for addressing high-unmet-need diseases such as eosinophilic esophagitis (EoE) and osteoarthritis of the knee.

Key Clinical and Corporate Developments

Advancement of EP-104GI for EoE: Eupraxia recently dosed its first patient in the Phase 2b placebo-controlled portion of the RESOLVE trial, building on encouraging data from the Phase 1b/2a cohort. In the most recent update, all three patients demonstrated sustained or improved treatment outcomes after nine months of therapy, with topline Phase 2b data expected in the second half of 2026.
Osteoarthritis Program Progress: The company showcased strong Phase 2 results for EP-104IAR in knee osteoarthritis at the 2024 EULAR European Congress of Rheumatology, indicating reduction in joint inflammation and improvements in cartilage quality compared to placebo—a value proposition that could disrupt the multi-billion dollar pain management market.
Strategic Financing and Corporate Strength: Eupraxia recently reported that the Company had cash of $19.8 million as of June 30, 2025, further supporting its research pipeline and clinical expansion efforts, including the upcoming data release from RESOLVE’s next cohorts in October 2025. The Company anticipates that existing cash reserves, and anticipated proceeds from the future exercise of in-the-money warrants, will be sufficient to fund the Company into the third quarter of 2026.

Near-Term Key Milestones & Wall Street Conferences

October 2025 – Additional Data Release: Eupraxia will announce results from cohorts 5–8 of its Phase 1b/2a RESOLVE trial for EP-104GI, targeting Eosinophilic Esophagitis (EoE). This data will provide critical insights into the drug’s durability and safety profile at higher doses.
Ongoing Enrollment in Phase 2b Trial: The company has begun enrolling patients in the Phase 2b, placebo-controlled portion of RESOLVE, aiming for a minimum of 60 patients across up to 25 global sites. Successful enrollment and retention will be crucial through 2025.
Topline Results from Phase 2b Expected in H2 2026: Eupraxia anticipates announcing topline data for the Phase 2b segment in the second half of 2026, with interim updates likely as trial milestones are met.
Major Investor Conferences (Q3 2025):
- Canaccord Genuity 45th Annual Growth Conference (August 12–14, 2025)
- Citi Biopharma Back to School Conference (September 2–3, 2025)
- Cantor Global Healthcare Conference (September 3–5, 2025)
- H.C. Wainwright 27th Annual Global Investment Conference (September 8–10, 2025)

Wall Street Ratings and Investment Bank Coverage

Strong Consensus Buy: Out of six Wall Street analysts covering the stock in the past twelve months, all have issued “Buy” or “Strong Buy” ratings for Eupraxia. The consensus price target stands at $11—more than double its current trading level, reflecting analysts’ optimism about the company’s growth trajectory and clinical catalysts.
Institutional Investor Confidence: Large institutional players such as Scotia Capital, Royal Bank of Canada, and JPMorgan have notably increased holdings in recent quarters, underlining sector confidence in the long-term fundamentals.

Strategic Support

On Oct. 31, 2024, Eupraxia announced that it had completed a non-brokered private placement for aggregate gross proceeds of C$44,528,190. In connection with the closing of the Private Placement, the Company appointed Mr. Joseph Freedman to its board of directors. Mr. Freedman is a private equity investor and corporate director with more than 25 years industry experience including, most recently, 18 years at Brookfield Asset Management, one of the world’s leading private equity and alternative asset management firms. Over his career at Brookfield, Mr. Freedman has held a number of positions, including Vice Chair of Private Equity, General Counsel and the Partner responsible for M&A transaction execution, fund formation and fund operations. Prior to joining Brookfield, he was a lawyer in the corporate finance group at a Toronto law firm, specializing in private equity transactions and public company mergers and acquisitions. Now retired from Brookfield, Mr. Freedman is a director of several private and public companies and non-profit organizations including the Centre for Aging and Brain Health Innovation (co-chair), Bridgemarq Real Estate Services (TSX:BRE) and Total Containment Inc. Mr. Freedman holds a joint MBA/LL.B from the Schulich School of Business at York University and Osgoode Hall Law School in Toronto.

The Sum…

Eupraxia’s (EPRX) growing string of positive clinical updates, new capital infusion, and unanimous Wall Street Buy ratings potentially position the company as a standout small-cap biotech with real near-term catalysts. As Phase 2b and additional cohort data for EP-104GI and EP-104IAR approach, the stock may see enhanced volatility and opportunity, reflecting its potential to shape new standard-of-care paradigms in inflammatory disease management.

Sources

by John F. Heerdink, Jr. August 28, 2025

Parkinson’s Drug Milestone: Serina Therapeutics Wins FDA Support, HCW Wainwright Reaffirms Buy Rating on SER Stock ( $SER $IBB $XBI )

HCW Wainwright has reiterated its Buy rating on Serina Therapeutics (NYSE American: SER), emphasizing both the company’s clinical progress and robust valuation metrics as key drivers for investor optimism.

Company Snapshot and Market Performance

Serina Therapeutics (SER) currently trades at $5.04 per share with a market capitalization of $51.62 million. HCW Wainwright’s analysts, Raghuram Selvaraju, Ph.D., and Daniel Smith, recently reaffirmed their Buy rating and 12-month price target of $15.00 for the stock, reflecting significant upside potential as the company advances its clinical pipeline based upon their novel & proprietary POZ platform technology that has been designed for programmable, targeted delivery of a broad range of small molecules. The technology has been clinically demonstrated to safely enable continuous drug delivery via a once weekly subcutaneous injection. The POZ platform is customizable, versatile and can be dosed via IV, SC or IM routes to address a broad range of clinical indications.

Regulatory Milestone: SER-252 Gets FDA Green Light

This week, Serina reported receiving written feedback from the FDA supporting advancement of its key asset, SER-252 (POZ-apomorphine), in a registrational clinical study for advanced Parkinson’s disease under the accelerated 505(b)(2) NDA pathway. The FDA’s feedback, based on a Type B meeting, enables Serina to leverage its proprietary POZ technology for controlled release, aiming to provide patients with more consistent relief from motor fluctuations while minimizing injection site reactions. Clinical development is set to initiate pharmacokinetic bridging to an approved apomorphine product. The anticipated U.S. IND filing in Q4 2025 is poised to kick off patient dosing in Australia by year-end and U.S. enrollment in early 2026. Initial clinical data could be available in the second half of 2026—a potential inflection point for the stock.

Strong Commercial Potential and Market Metrics

Parkinson’s disease (PD) afflicts over 1 million people in the U.S., with about 150,000 suffering from advanced PD who may benefit from SER-252. Comparable currently approved therapies are priced at up to $119,000 per year, positioning Serina’s conservative pricing assumptions of $50,000 (U.S.) and $35,000 (Europe) as highly competitive yet capable of yielding forecasted peak annual sales exceeding $1.1 billion across major markets by 2040.

International Approval Footprint for enFuse Delivery

The enFuse® delivery device for SER-252 has just received market authorization from Brazil’s ANVISA, and earlier in 2025, secured registration with the UK regulator (MHRA) and CE Mark for the EU. This regulatory momentum bodes well for SER-252’s global adoption prospects.

Pipeline Expansion and Long-Term Upside

Serina’s second clinical candidate, SER-270 (POZ-VMAT2i), advances in the lucrative tardive dyskinesia market, with additional applications in Huntington’s chorea under evaluation. Current forecasts do not assign value to SER-270, leaving significant room for pipeline-driven upside as development progresses.

Financial Health and Valuation

As of mid-2025, Serina reported roughly $6 million in cash following a stock sale. HCW’s DCF valuation approach models a 12% discount rate, 2% terminal growth, and a conservative 40% probability of approval for SER-252, resulting in an enterprise value of $300 million and the $15 price target.

Risks and Analyst Caution

Potential risks include delays in clinical progression, regulatory setbacks, slower-than-expected commercial uptake, competitive dynamics, partnership uncertainties, and possible near-term dilution.

SOURCES

by John F. Heerdink, Jr. August 27, 2025

Stock Buybacks Hit Historic Highs: What Wall Street’s 2026 $1.2 Trillion Spree Means for Investors – ( $AAPL $BAC $GOOG $JPM $NVDA $META $MS )

U.S. corporations have crossed an extraordinary threshold in 2025, shattering records by eclipsing $1 trillion in share buybacks before the close of August—faster than any year in history. This landmark moment underscores a potent undercurrent of confidence among America’s corporate titans, driven by resilient earnings, robust cash flows, and a desire to reward shareholders amid a backdrop of mounting economic uncertainty.

Record-Breaking Pace Led by Tech and Banks

Buybacks reportedly surged past the $1 trillion milestone as of August 20, rapidly outpacing prior years, with projections suggesting completed repurchases could reach $1.1 trillion by year-end and announced authorizations topping $1.3 trillion. Market analysis from Birinyi Associates notes that it’s not just the scale but also the speed that distinguishes this year’s spree, marking the shortest time interval on record for hitting such heights.

At the vanguard of this buyback wave are familiar heavyweights. Apple (AAPL) led the charge, announcing an eye-popping $100 billion buyback program, while Alphabet (GOOG) and JPMorgan Chase (JPM) revealed plans to repurchase $70 billion and $50 billion of their own shares, respectively. Together with other tech and banking stalwarts—Meta (META), Nvidia (NVDA), Bank of America (BAC), and Morgan Stanley (MS)—the top 20 U.S. companies comprised nearly half of all buybacks.

Economic Engines and Shareholder Rewards

The buyback blitz has dovetailed with strong earnings—82% of S&P 500 companies beat second-quarter estimates, further emboldening boards to return capital. The rationale for these programs is twofold: repurchases engineer higher earnings per share by shrinking outstanding share counts and serve as a direct reward to shareholders, often supporting stock prices during patchy market conditions.

Strategists from Citadel Securities calculate that at current activity levels, buybacks translate into roughly $4.4 billion a day in net buying, fortifying demand for equities even as public investor sentiment vacillates. This dynamic has been a silent pillar sustaining Wall Street’s rally throughout 2025.

Dissenting Voices: R&D or Returns?

Still, the voracious pace has reignited perennial debates about corporate priorities. Critics, including some government officials, worry that the emphasis on buybacks diverts critical capital from innovation, long-term growth, and resiliency, particularly in sensitive sectors like aerospace. Treasury officials have pointedly rebuked large manufacturers like Boeing (BA) for what they see as a shortsighted preference for buybacks over reinvestment in research and development.

Broader Context and Historical Nuance

The 2025 surge, though historic, follows established trends. In 2024, S&P 500 firms spent nearly $943 billion on buybacks—a 20% year-over-year increase—and global counterparts, though more measured, have reflected a similar appetite for capital returns. Notably, analysts expect that if historical execution rates persist (typically around 90%), total stock buybacks could touch a new high of $1.2 trillion by 2026.

The Road Ahead

With boards flush with cash but capital expenditures slowing amidst trade frictions, the calculus for buybacks appears unchanged heading into the final months of the year. As the corporate blackout period approaches in mid-September, the velocity of repurchases may moderate, but for now, buybacks remain a crucial driver—at once a sign of enduring corporate strength and a lightning rod for debate about Wall Street’s true priorities.

SOURCES

by John F. Heerdink, Jr. August 27, 2025

How MongoDB’s Product Innovations and AI Partnerships Are Fueling a Bullish Outlook ( $MDB $QQQ )

MongoDB, Inc. (MDB) is riding a wave of momentum, decisively positioning itself as a foundational enabler of the artificial intelligence revolution with robust financials, rapid customer growth, and strategic innovation initiatives. Over the past several months, a steady cadence of announcements—ranging from standout earnings to bold product advancements—has underscored MongoDB’s expanding role at the intersection of next-generation data technologies and enterprise demand.

Standout Financial Performance

MongoDB recently reported second-quarter fiscal 2026 revenue of $591.4 million, a 24% year-over-year increase, handily beating Wall Street forecasts. Atlas, the company’s flagship cloud platform, grew 29% and now represents 74% of total revenues, reflecting broad adoption across industries. Notably, MongoDB added over 2,800 new customers in Q2 alone, with year-to-date additions surpassing 5,000—the highest in its history. Management has responded to this strength by raising full-year financial guidance, signaling confidence in sustained, profitable growth.

Fueling the AI Ecosystem

Multiple press releases highlight MongoDB’s aggressive buildout as a core database provider for the AI era. The company is fortifying its AI application foundation with advanced search, vector search, and a flexible document model designed specifically for the demands of AI workloads. The August 2025 launch of new product innovations and an expanded partner ecosystem directly targets the escalating need for robust, enterprise-grade infrastructure supporting generative AI platforms.

Strategic Expansion and Trust Initiatives

Beyond the commercial sector, MongoDB is pushing into regulated markets with commitments to FedRAMP High and DoD Impact Level 5 authorizations for its Atlas for Government product, addressing the security and compliance needs of U.S. federal agencies. The company also enhanced its growth playbook with key executive hires, including new CFO Mike Berry, and broadened reach by listing MongoDB Enterprise Advanced on AWS Marketplace for the U.S. Intelligence Community.

M&A and AI-First Partnerships

Earlier in 2025, MongoDB acquired Voyage AI, a move that instantly deepened its AI search capabilities and brought onboard a team specializing in trustworthy, real-world AI applications. The firm’s ongoing collaborations—such as with Lombard Odier to modernize core banking using generative AI—demonstrate both industry credibility and a clear strategy to be the connective tissue in AI-driven digital transformation.

Developer-Led, Customer-Centric Growth

MongoDB’s .local event series, spanning major global tech hubs, has accelerated developer adoption and provided hands-on experience for building AI-powered solutions. This developer-first ethos, long at the core of MongoDB’s brand, remains central as the company empowers organizations to build, deploy, and scale AI applications securely and efficiently.

Recognition and Market Validation

Recent industry accolades include leadership placement in the 2024 Gartner® Magic Quadrant™ for Cloud Database Management Systems and being voted a top vector database in 2024. Despite broader software sector headwinds, MongoDB stock surged after its Q2 results, as the market recognized its agility in addressing both short-term uncertainty and long-term opportunity in AI infrastructure.

The Sum…

In sum, MongoDB’s relentless execution and forward-looking strategy are transforming it into an indispensable linchpin of enterprise technology stacks, especially for organizations hungry to capitalize on the AI-driven future. The company’s seamless blend of innovation, scale, and trust is crafting a growth narrative worthy of bullish investor attention.

Sources

Recent Highlights and Stock Momentum

Underlying Business Strengths

Financial Outlook and Valuation

Strategic Position and Growth Catalysts

Bottom Line

Sources

Anglo American–Teck Merger

Hecla Mining: Resilient Performance

Strategic Landscape

Sources

Jensen Huang: Founder, Strategist, Risk-Taker

Leadership Through Tech Revolutions

Rewards for Investors and the Industry

Enduring Legacy and Impact

The Sum…

Sources:

Steven Ledger’s Vision

Breaking Through in Parkinson’s

Regulatory and Market Traction

Sources

Central Banks Shift to Gold

Reasons for Accelerated Gold Buying

Impact on Global Markets

Leading Holders and Strategic Shifts

The Road Ahead

Sources

Groundbreaking Clinical Progress

Understanding Eosinophilic Esophagitis

Current Treatment Landscape and Its Shortcomings

Eupraxia Pharmaceuticals’ Proprietary DiffuSphere™ Technology

Business Momentum, Analyst Confidence, and Industry Leadership

The Road Ahead

Sources

Key Clinical and Corporate Developments

Near-Term Key Milestones & Wall Street Conferences

Wall Street Ratings and Investment Bank Coverage

Strategic Support

The Sum…

Sources

Company Snapshot and Market Performance

Regulatory Milestone: SER-252 Gets FDA Green Light

Strong Commercial Potential and Market Metrics

International Approval Footprint for enFuse Delivery

Pipeline Expansion and Long-Term Upside

Financial Health and Valuation

Risks and Analyst Caution

Record-Breaking Pace Led by Tech and Banks

Economic Engines and Shareholder Rewards

Dissenting Voices: R&D or Returns?

Broader Context and Historical Nuance

The Road Ahead

Standout Financial Performance

Fueling the AI Ecosystem

Strategic Expansion and Trust Initiatives

M&A and AI-First Partnerships

Developer-Led, Customer-Centric Growth

Recognition and Market Validation

Your Guide To Staying Informed In The Markets